About Us

Functional Neuromodulation Ltd. (FNM) is advancing deep brain stimulation (DBS) therapies to help improve the lives of people with mild Alzheimer’s disease. The company, founded in 2010 by Andres Lozano, MD, scientific founder and principal inventor is investigating the use of DBS of the fornix (DBS-f) to drive neural activity and modulate the brain’s memory circuit. FNM is in a strategic investment partnership with Boston Scientific. Genesys Capital is also an investor. The company completed the ADvance Study, a multi-center feasibility study of DBS-f in 42 patients with mild Alzheimer’s disease. The ADvance Study was also supported through a translational grant of up to $2.75M from the National Institute on Aging, part of the National Institutes of Health. Based on the promising results ADvance, FNM is now conducting a phase III trial, ADvance II, to establish the safety and efficacy of DBSf for Alzheimer’s disease. The CE mark (European regulatory approval) was obtained for DBS-f for Alzheimer’s disease in 2017.

CAUTION — Investigational device. Limited by Federal law to investigational use.